Metabolic engineering of HEK293 cells to improve transient transfection and cell budding of HIV‐1 virus‐like particles

Jesús Lavado‐García,Andy Díaz‐Maneh,Núria Canal‐Paulí,Pol Pérez‐Rubio,Francesc Gòdia,Laura Cervera
DOI: https://doi.org/10.1002/bit.27679
IF: 3.8
2021-01-25
Biotechnology and Bioengineering
Abstract:<p>HIV‐1 Gag virus‐like particles (VLPs) are promising candidates for the development of future vaccines. Recent viral outbreaks have manifested the need of robust vaccine production platforms able to adapt to new challenges while achieving mass production capacity. For the rapid production of VLPs, the method of transient gene expression (TGE) have proved highly efficient. Based on a previous characterization of the HEK293 cell line upon transient transfection using multiplexed quantitative proteomics, molecular production bottlenecks and metabolic pathways likely to be optimized were identified. In this work, these molecular components and metabolic pathways have been explored and modulated via transient metabolic engineering using approaches like design of experiments (DoE) to fully exploit and optimize VLP production, transfection and budding efficiency. Upon overexpression of endosomal sorting complex required for transport (ESCRT) accessory proteins like NEDD4L and CIT, VLP production increased 3.3 and 2.9‐fold respectively. Overexpression of glycosphingolipid precursor enzyme UGCG improved transfection efficiency by 17% and knocking‐down the Gag‐binding protein CNP improved 2.5‐fold VLP specific productivity. Combining CNP inhibition and UGCG overexpression further improved budding efficiency by 37.3%. Modulating VLP production and accessory pathways like intracellular budding, demonstrated the potential of metabolic engineering to optimize and intensify the development of robust production platforms for future vaccines.</p><p>This article is protected by copyright. All rights reserved.</p>
biotechnology & applied microbiology
What problem does this paper attempt to address?